Botto G L, Bonini W, Broffoni T, Cappelletti G, Falcone C, Lombardi R, Paulesu A, Pedraglio E, Ferrari G
Department of Cardiology, St. Anna Hospital, Como, Italy.
Pacing Clin Electrophysiol. 1994 Nov;17(11 Pt 2):2114-7. doi: 10.1111/j.1540-8159.1994.tb03810.x.
The incidence of fast atrial tachycardias with regular ventricular rhythm was assessed in a population of 243 patients with recent onset (< 72 hours) atrial fibrillation (AF), without heart failure, randomly treated with single loading oral dose of propafenone (600 mg), flecainide (300 mg), digoxin (1 mg), or placebo for acute conversion to sinus rhythm (SR). Fast atrial arrhythmias developed in 14 (6%) patients: 6/92 treated with propafenone, 3/34 treated with flecainide, 1/25 treated with digoxin, and 4/92 who received placebo (P = NS). Heart rate > 175 beats/min with 1:1 AV conduction ensued in 4 cases: 2 treated with flecainide and 2 treated with placebo; in the other cases 2:1 AV conduction was observed. Widening of QRS during regular tachycardia was observed in 4 patients; 3 who received propafenone and 1 who received flecainide. Conversion to SR within 4 hours was achieved in 55/92 (60%) patients treated with propafenone, 20/34 (59%) patients treated with flecainide, 7/25 (28%) patients treated with digoxin, and 19/92 (20%) treated with placebo (P < 0.001 propafenone vs placebo and flecainide vs placebo; P < 0.05 propafenone vs digoxin and flecainide vs digoxin). Periods of regular tachycardia are expected in recent onset AF and may not necessarily represent a proarrhythmic effect of Class 1C drugs, rather than mark the transition from AF to SR. Class 1C agents are probably responsible for widening of the QRS complex seen during these tachycardias. Propafenone and flecainide appear equally effective in converting recent onset AF.
在243例近期发作(<72小时)的心房颤动(AF)患者中评估了伴有规则心室节律的快速房性心动过速的发生率,这些患者无心力衰竭,随机接受单次口服负荷剂量的普罗帕酮(600mg)、氟卡尼(300mg)、地高辛(1mg)或安慰剂进行急性转复为窦性心律(SR)。14例(6%)患者出现快速房性心律失常:普罗帕酮治疗组92例中有6例,氟卡尼治疗组34例中有3例,地高辛治疗组25例中有1例,安慰剂组92例中有4例(P=无显著性差异)。4例患者出现心率>175次/分且房室传导比例为1:1:2例接受氟卡尼治疗,2例接受安慰剂治疗;其他病例观察到2:1房室传导。4例患者在规则性心动过速期间观察到QRS波增宽;3例接受普罗帕酮治疗,1例接受氟卡尼治疗。普罗帕酮治疗组92例中有55例(60%)、氟卡尼治疗组34例中有20例(59%)、地高辛治疗组25例中有7例(28%)、安慰剂组92例中有19例(20%)在4小时内转复为SR(普罗帕酮与安慰剂、氟卡尼与安慰剂相比,P<0.001;普罗帕酮与地高辛、氟卡尼与地高辛相比,P<0.05)。近期发作的AF患者预计会出现规则性心动过速期,这不一定代表1C类药物的促心律失常作用,而可能标志着从AF向SR的转变。1C类药物可能是这些心动过速期间出现QRS波增宽的原因。普罗帕酮和氟卡尼在转复近期发作的AF方面似乎同样有效。